Danvatirsen - AstraZeneca/Ionis Pharmaceuticals

Drug Profile

Danvatirsen - AstraZeneca/Ionis Pharmaceuticals

Alternative Names: AZD-9150-sodium; AZD9150; Danvatirsen-sodium; IONIS-STAT3-2.5Rx; IONIS-STAT3Rx; ISIS-345794; ISIS-481464; ISIS-STAT3-2.5Rx; ISIS-STAT3Rx; STAT3Rx

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly; Isis Pharmaceuticals
  • Developer AstraZeneca; Ionis Pharmaceuticals; MedImmune; National Cancer Institute (USA)
  • Class Antineoplastics; Antisense oligonucleotides
  • Mechanism of Action STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer; Head and neck cancer; Malignant ascites; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
  • Phase I/II Liver cancer; Non-Hodgkin's lymphoma
  • Phase I Diffuse large B cell lymphoma

Most Recent Events

  • 22 Oct 2018 Efficacy data from the phase Ib/IISCORES trial in Head and neck cancer released by Astrazeneca
  • 24 Jun 2018 Biomarkers information updated
  • 01 Jun 2018 Phase-I clinical trials in Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) in USA (IV) (NCT03527147)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top